Skip to main content
RPID
NASDAQ Industrial Applications And Services

Rapid Micro Posts 22% Q3 Revenue Growth, Withdraws Guidance Amid Merck Buyout

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$0.735
Mkt Cap
$36.867M
52W Low
$0.58
52W High
$4.94
52W Position info
27% above low
Off High info
85% below high
Rel. Volume info
13× avg
Market data snapshot near publication time

RPID sits 27% above its 52-week low of $0.58 on elevated volume (13× avg).

Summary

Rapid Micro Biosystems reported 22% Q3 revenue growth to $9.5 million and a record 25% gross margin, but cash fell to roughly $7 million. The company withdrew 2026 guidance and delayed its 10-Q as it moves toward being acquired by Merck KGaA.


Key Events · Earnings and Guidance · RPID

  • Q3 Revenue Grows 22% to $9.5M

    Total revenue rose 21.6% to $9.5 million from $7.8 million a year earlier, with product revenue up 24.9% to $6.5 million and service revenue up 14.9% to $3.0 million.

  • Record 25% Gross Margin

    Gross margin reached 25.2%, or $2.4 million, versus 8.9% ($0.7 million) in Q3 2025; product gross margin rose 19 points to 12% and service margin rose 14 points to 54%.

  • Cash Falls to About $7M

    Cash, cash equivalents and short-term investments were approximately $7 million at September 30, 2026, down from $38.3 million at December 31, 2025 ($20.0 million cash plus $18.3 million short-term investments).

  • Guidance Withdrawn, 10-Q Delayed

    The company withdrew full-year 2026 guidance, canceled its Q3 earnings call, and will delay its Form 10-Q, intending to file within the Rule 12b-25 extension period.


Analysis · RPID · Industrial Applications And Services

Operationally the business is improving: revenue rose 22% to $9.5 million and gross margin hit a record 25%. The balance sheet, however, tells the more urgent story. Cash and short-term investments fell to about $7 million from $38.3 million at year-end 2025, and that runway pressure is presumably why the company is being sold to Merck KGaA rather than staying independent. With full-year 2026 guidance withdrawn and the 10-Q delayed, these reported figures are the last clean look at the standalone business before the tender offer plays out.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RPID was trading at $0.73 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $36.9M. The 52-week trading range was $0.58 to $4.94. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RPID - Latest Insights

RPID
Nov 16, 2026, 9:26 AM EST
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $0.675
Real-time Price: $0.7369 info
Change: +$0.0619 (+9%) info
Market Cap: $36.867M info
RPID
Aug 07, 2026, 7:33 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.08
Real-time Price: $0.7369 info
Change: -$1.34 (-65%) info
Market Cap: $36.867M info
RPID
Aug 07, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.08
Real-time Price: $0.7369 info
Change: -$1.34 (-65%) info
Market Cap: $36.867M info
RPID
May 19, 2026, 5:23 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.98
Real-time Price: $0.7369 info
Change: -$1.24 (-63%) info
Market Cap: $36.867M info
RPID
May 19, 2026, 5:13 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.98
Real-time Price: $0.7369 info
Change: -$1.24 (-63%) info
Market Cap: $36.867M info